New Hybrid Treatment Forces Cancer Cells to Starve
NEW YORK, Dec. 9, 2023 /PRNewswire/ -- The combination of a drug and a protein fragment prevents the growth of blood cancer cells, a new study in mice shows. The work addressed multiple myeloma, a cancer that forms in blood cells that normally fight infections by making proteins that... (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - December 9, 2023 Category: Pharmaceuticals Tags: TRI Source Type: news
In Real World, Patients With Myeloma Have Worse Outcomes In Real World, Patients With Myeloma Have Worse Outcomes
A new analysis found that patients with multiple myeloma receiving standard therapies have much worse outcomes compared with those treated in clinical trials.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - December 9, 2023 Category: Consumer Health News Tags: Hematology-Oncology Source Type: news
Multiple Myeloma: Clinical Challenges for the Community Clinician Multiple Myeloma: Clinical Challenges for the Community Clinician
Medscape_Education_No_Bots (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - December 8, 2023 Category: Consumer Health News Tags: Roundtable Source Type: news
Time to Stop Routine Maintenance Therapy in Myeloma? Time to Stop Routine Maintenance Therapy in Myeloma?
Physicians may need to rethink maintenance with lenalidomide (Revlimid and generics) for multiple myeloma.MDedge News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - December 1, 2023 Category: Cancer & Oncology Tags: Hematology-Oncology Source Type: news
GSK Frames A Comeback For Its Multiple Myeloma Drug Following Encouraging Phase 3 Data
GSK plc GSK announced headline results from a planned interim efficacy analysis of the DREAMM-7 head-to-head phase 3 trial evaluating belantamab mafodotin as a second-line treatment for relapsed or refractory multiple myeloma. The study included 494 patients previously treated with at least one…#gskplc #gsk #belantamabmafodotin #bordex #00005 #fda #phase3 #dreamm (Source: Reuters: Health)
Source: Reuters: Health - November 27, 2023 Category: Consumer Health News Source Type: news
From Hospice to Helping Others: Brent Rutemiller's Remarkable Battle Against Multiple Myeloma
"Rutemiller's Army" Helps Brent Rutemiller Fight His Own Cancer and is Making Waves to Fight Cancer with Swim Across America PHOENIX, Nov. 16, 2023 /PRNewswire-PRWeb/ -- In June 2023, Brent Rutemiller, former publisher of Swimming World Magazine and former CEO of the International Sports... (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - November 16, 2023 Category: Pharmaceuticals Source Type: news
Mount Sinai Researchers Receive $7 Million to Improve Outcomes for High-risk Blood Cancer Patients From the Multiple Myeloma Research Foundation
The Mount Sinai Health System has received a $7 million grant from the Multiple Myeloma Research Foundation for a three-year project that aims to fast-track novel translational concepts to improve outcomes for people with high risk myeloma, the second most common blood cancer in the... (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - November 2, 2023 Category: Pharmaceuticals Tags: PDT Source Type: news
Roche to present new data at ASH 2023 showcasing breadth of haematology portfolio spanning 10 different types of blood disorders
Basel, 2 November 2023 – Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today it will be presenting more than 45 abstracts at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition, spanning 10 haematology indications.New data reflect Roche ’s commitment to advancing treatment standards even further to help improve the lives of people with blood disorders. This includes new areas, as well as diseases where its medicines have already changed the standard of care, such as haemophilia A, diffuse large B-cell lymphoma (DLBCL) and follicu lar lymphoma (FL). These data also support Roche’s mission to dev...
Source: Roche Investor Update - November 2, 2023 Category: Pharmaceuticals Source Type: news
Arnold Diaz Dies: Emmy Winning CBS Reporter Known For His ‘Shame On You’ Segment Was 74
Investigative reporter Arnold Diaz, whose popular “Shame On You” consumer series ran for more than 20 years, has died at 74-after battling multiple myeloma. Diaz retired in 2022 after a 50-year career in television journalism, during which he won 48 Emmy Awards. One of the original television news…#arnolddiaz #abc #wnyw #shameshameshame (Source: Reuters: Health)
Source: Reuters: Health - October 27, 2023 Category: Consumer Health News Source Type: news
Racial, Ethnic Differences ID'd for Idecabtagene Vicleucel in Multiple Myeloma
WEDNESDAY, Oct. 25, 2023 -- There are some racial and ethnic differences in safety and response to standard of care (SOC) idecabtagene vicleucel (ide-cel) in patients with relapsed/refractory multiple myeloma (RRMM), according to a study published... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - October 25, 2023 Category: Pharmaceuticals Source Type: news
Quad Regimen for High-Risk Myeloma Produces High Rates of Durable MRD Negativity
(MedPage Today) -- A four-drug regimen for newly diagnosed high-risk multiple myeloma induced high rates of sustained minimal residual disease (MRD) negativity regardless of transplant status, a German research group reported.
Two-thirds of transplant... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - October 19, 2023 Category: Hematology Source Type: news
J & J ’s Medical Device Sales Feel the Side Effects of Weight-Loss Drugs
Riding high, Johnson & Johnson reported pharmaceutical sales worth $13.89 billion on Tuesday (Oct 17), a year-over-year growth exceeding 5%. The pharmaceuticals driving its growth are Darzalex, a biologic used for multiple myeloma, and Erleada, a prostate cancer treatment, in addition to several…#johnsonjohnson #darzalex #erleada #imbruvica #abiomed #altopharmacy #teamcubancard #medtechdivision #obese #glp1 (Source: Reuters: Health)
Source: Reuters: Health - October 18, 2023 Category: Consumer Health News Source Type: news
PET/CT radiomics may improve diagnosis of VCFs
In this study, the researchers aimed to combine FDG-PET/CT features and CT features in a radiomics model that could help clinicians make treatment decisions in these cases.The researchers analyzed imaging from 439 patients diagnosed with vertebral compression fractures after PET/CT scans at their hospital from January 2016 to January 2023. They extracted 26 features from the imaging: nine PET features and 17 CT features, as well as eight clinical variables, such as age, maximum standard uptake value (SUVmax) of FDG radiotracer, osteolytic destruction, and fracture line, for instance.Using these, the group constructed a com...
Source: AuntMinnie.com Headlines - October 17, 2023 Category: Radiology Authors: Will Morton Tags: Clinical News Molecular Imaging Source Type: news
Survival on the Upswing in Multiple Myeloma Survival on the Upswing in Multiple Myeloma
Hematologists are heralding a new era in multiple myeloma. Experts discuss how times have changed.MDedge News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - October 12, 2023 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
Diabetes More Prevalent in Black Patients With Multiple Myeloma
FRIDAY, Oct. 6, 2023 -- Diabetes mellitus (DM) is more prevalent among Black patients with multiple myeloma (MM) and is associated with overall survival in MM, especially among White patients, according to a study published online Sept. 29 in Blood... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - October 6, 2023 Category: Pharmaceuticals Source Type: news
